KJ-C2114 / CARsgen - LARVOL DELTA

A phase I study of anti-GPC3 chimeric antigen receptor modified T cells (GPC3 CAR-T) in Chinese patients with refractory or relapsed GPC3+ hepatocellular carcinoma (r/r GPC3+ HCC). (ASCO 2017) - P1; "Phase I trial shows GPC3 CAR-T is feasible and safe for Chinese pts with r/r GPC3+ HCC, and holds promising antitumor potential when LDC is applied along with GPC3 CAR-T."

Adverse events • Clinical • P1 data • Biosimilar • Gene Therapies • Hepatocellular Cancer • Immunology

Phase I trial of Claudin 18.2-specific chimeric antigen receptor T cells for advanced gastric and pancreatic adenocarcinoma. (ASCO 2019) - P=N/A; "Background: As a promising approach for some cancers, chimeric antigen receptor T cell therapy has limited success in solid tumors... In this single-arm, open-label, first-in-human phase I pilot study (NCT03159819) to investigate the safety and explore the efficacy of the autologous CAR-CLDN18.2 T cells, patients with confirmed CLDN 18.2 positive advanced gastric or pancreatic adenocarcinoma aged 18 to 70 years received 1 or more cycles of CAR-CLDN18.2 T cell infusion(s) after lymphodepletion pretreatment (fludarabine and cyclophosphamide, with or without nab-paclitaxel) until disease progression or presence of intolerable toxicity... This clinical study indicated that CAR-CLDN18.2 T cell therapy were safe and well tolerated and may have promising therapeutic efficacy in patients with advanced gastric and pancreatic adenocarcinoma. Clinical trial information: NCT03159819"

CAR T-Cell Therapy • P1 data • Gastric Cancer • Gastrointestinal Cancer • Oncology • Pancreatic Cancer

THE EFFICACY AND SAFETY OF HUMANIZED CD19 CAR-T CELLS FOR RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (NHL): A PRELIMINARY REPORT (EHA 2018) - P1; "...Patients received a conditioning chemotherapy regimen of cyclophosphamide and fludarabine followed by infusion of CD19CAR-Tcells...Patient 3 had DLBCL (double-expressor lymphoma) diagnosed in 2017, obtained partial remission (PR) after 3 cycles of R-CHOP and progressed after additional 3 cycles of same regimen... This is the first report of successful treatment of R/R B-cell NHL with humanized CD19 CAR-T cells. The efficacy and safety demonstrated by these preliminary results provides strong support for further study of this approach."

CAR T-Cell Therapy • Clinical • Diffuse Large B Cell Lymphoma • Mantle Cell Lymphoma

"#RAReports Over 100 companies are involved in development of CAR-T therapies. Some key players include @JunoThera ,Marino Biotechnology, @CellBioMedGroup @Novartis @Celgene , CARsgen Therapeutics, Shanghai GeneChem For insights on CAR-T Therapies Market: https://t.co/jQr6OGp5NP" (@RootsAnalysis)

CT053, Anti-BCMA CAR T-cell therapy for Relapsed/Refractory Multiple Myeloma: Proof of Concept Results from a Phase I Study (IMW 2019) - P=N/A, P1; " Patients with relapsed/refractory multiple myeloma (rrMM) who received at least 2 prior lines of therapies and between 18-79 years of age, received 1 single CT053 infusion after fludarabine/cyclophosphamide treatment. This study demonstrated that CT053 had an excellent efficacy and a good safety profile in patients with rrMM."

CAR T-Cell Therapy • P1 data

4th Generation Chimeric Antigen Receptor T Cells Targeting Glypican-3 (clinicaltrials.gov) - P1; N=36; Not yet recruiting; Sponsor: Zhejiang University

Clinical • New P1 trial

Clinical Trial to Evaluate BCMA Car-T (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - P1/2; N=84; Not yet recruiting; Sponsor: Carsgen Therapeutics, Ltd.

Clinical • New P1/2 trial

"3a) Bayer/Amgen BiTE PSMA; 3b) CARsgen CLDN18.2 CART" (@showmetheDD)

Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors. (clinicaltrials.gov) - P1; N=15; Recruiting; Sponsor: Peking University; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

Chimeric Antigen Receptor T Cells Targeting Glypican-3 (clinicaltrials.gov) - P1; N=15; Not yet recruiting; Sponsor: Carsgen Therapeutics, Ltd.

Clinical • New P1 trial

Chimeric Antigen Receptor T Cells Targeting Glypican-3 (clinicaltrials.gov) - P1; N=15; Not yet recruiting; Sponsor: Peking University

Clinical • New P1 trial